Slide 1: ViewRay: Visibly Different
Exhibit 99.2 VIEWRAY Vi Visibly Different January 2020 CS VIEWRAY
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “
Slide 3: Clearly Differentiated Technology
Clearly Differentiated Technology Moving to personalized care RADIATION ONCOLOGY SURGERY MEDICAL ONCOLOGY
Slide 4: The Evolution of Radiation Therapy
MRIDIAN XRAY CONE BEAM CT The Evolution of Radiation Therapy
Slide 5: MRIdian: Clearly Differentiated Technology
MRIdian Market-leading CT LINAC Images courtesy of Amsterdam UMC Clearly Differentiated Technology When a millimeter is a mile
Slide 6: Proven next-generation radiation therapy
Proven next-generation radiation therapy Differentiated: safely delivers high-dose, adaptive, beam-gated SBRT Significant reduction in toxicities across a variety of tumor sites1,2,3,4,5,6 Surpassing 6,500* patients 100s of peer-reviewed journal articles and abstracts proving clinical utility MRIdia
Slide 7: MRIdian is the only system that
MRIdian is the only system that: Offers personalized, precision radiation therapy Sees and tracks tumors in real-time Provides automatic beam gating for precise and accurate dosing Enables complete, on-table re-optimization of treatment plans Defining & Delivering A NEW STANDARD OF CARE
Slide 8: Key Opinion Leader Perspective
Key Opinion Leader Perspective Daphne A. Haas-Kogan, MD Chair, Radiation Oncology Dana-Farber Cancer Institute Brigham and Women's Hospital and Boston Children's Hospital Just as the two-dimensional x-rays we relied on in the 1980s were replaced by CT-guided radiotherapy, so will MR-guided radiation
Slide 9: Seeing is Believing
Moments later in treatment Day of treatment planning During treatment MRIdian adapts to changes in size, shape, and location of tumors, organs at risk, and soft tissue Images courtesy of Henke et al. Int J Radiation Oncol Bio Phys Motion: MRI real-time, on-table adaptive with high-dose, beam-gated t
Slide 10: Making the Invisible Visible
Making the Invisible Visible M. Salim Siddiqui, MD Director, Stereotactic Radiation Program and MR Simulation Program Henry Ford Cancer Center This would have been unimaginable before MRIdian. “ Image and quote courtesy of Siddiqui, S. (2018). MR Image-Guided RT Case Review: Making the Invisible, Vi
Slide 11: Beyond a Treatment
Beyond a Treatment We are advancing cancer care. In the MRIdian vault, this is where we cure cancer. Down the hall they treat it. “ Clinician Amsterdam UMC Upon completing 36Gy in a single fraction to treat lung cancer “
Slide 12: How We Win
How We Win Commercial Organization Customer Service Operational Excellence Therapy Adoption via Innovation, Clinical Data, & Training
Slide 13: Bold Commercial Strategy
Bold Commercial Strategy Providing access and serving more patients Built commercial team, building distribution network Initial focus on United States, EMEA, and Japan This is ~70% of market opportunity Markets & Markets, 2015 Radiotherapy Market Global Forecasts 2020
Slide 14: Relentless Focus on Operational Excellence
Relentless Focus on Operational Excellence Vault readiness Installation Manufacturing efficiencies, supply chain management Driving efficiency across the organization
Slide 15: Customer Service
Customer Service Radical customer delight World-class service and support Clinical workflow Innovation, clinical data, and training
Slide 16: Extending our leadership position
Extending our leadership position Investing in innovation Machine vision, biologic imaging Simplified workflow Faster treatment times “Groundbreaking” long-term pipeline Game-changing Technological Innovation Therapy Adoption
Slide 17: Over 6,500 Patients Treated Globally - Early, Compelling Data
Increase in Overall Survival with simultaneous vanishing of Grade 3+ Toxicity in unresectable pancreatic cancer1,2,3,4 Ability to treat prostate with very high doses in few sessions with very low toxicity5, even in high risk populations12 Ability to treat partial breast with very high doses in few s
Slide 18: Selected Fourth Quarter and Full Year 2019 Preliminary Results
Selected Fourth Quarter and Full Year 2019 Preliminary Results ©2019 ViewRay, Inc. All rights reserved. Total revenue of approximately $17 million in the fourth quarter of 2019, primarily from three revenue units including one system upgrade, compared to total revenue of $21 million, primarily from
Slide 19: Investment Highlights
Investment Highlights Large Market Opportunity Paradigm Shift in MR-technology to Standard of Care Experienced Management Team Growing Clinical Data Compendium In-line with Market Trends: Non-invasive, Precise, Personalized Medicine Investing in Innovation to Extend Lead
Slide 20: Boldly Innovative. Clinically Driven. Committed to Conquering Cancer.
BOLDLY INNOVATIVE. CLINICALLY DRIVEN. COMMITTED TO CONQUERING CANCER.
Slide 21: References
1 Dr. Henke, ASTRO 2018, https://vimeo.com/298626732#t=458 2 Dr. Bassetti, Miami Symposium 2018, https://vimeo.com/293472071#t=1224 3 Dr. Parikh ASTRO 2017 Abstract, ASTRO 2017 multi-institutional, https://www.redjournal.org/article/S0360-3016(17)32096-5/fulltext 4 Washington University, Abstract fr